Publications by authors named "Rom Leidner"

Claim this Profile
A
Approaches to overcome the current treatment plateau in immunotherapy.
Anna Maria Di Giacomo, Renzo Canetta, John Connolly, Rom Leidner, Wei Zheng

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Robert L Ferris, Rom S Leidner, Christine H Chung, Antonio Jimeno, Sylvia M Lee

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso, Rom S Leidner

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.
Alexa K Dowdell, Ryan C Meng, Ann Vita, Bela Bapat, Douglas Hanes, Rom Leidner

JCO Oncol Pract· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Rom S Leidner

JCO Precis Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng

Cancer Immunol Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Junping Li, Hong Hu, Hui Lian, Shuo Yang, Manting Liu, Rom Leidner

Int J Biol Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta

J Immunother Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, Marc S Ernstoff, Bernard A Fox, Rom S Leidner

J Transl Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
Bernard A Fox, Walter J Urba, Shawn M Jensen, David B Page, Brendan D Curti, Rom S Leidner

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.
Maura L Gillison, Robert L Ferris, Jonathan Harris, A Dimitrios Colevas, Loren K Mell, Rom S Leidner

Int J Radiat Oncol Biol Phys· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies.
David Knorr, Rom Leidner, Shawn Jensen, Ryan Meng, Andrew Jones

bioRxiv· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck.
Brian J Park, Austin K Mattox, Daniel Clayburgh, Mihir Patel, R Bryan Bell, Rom Leidner

Oral Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply.
Eric Tran, Walter J Urba, Rom Leidner

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.
Thomas Duhen, Michael J Gough, Rom S Leidner, Sasha E Stanton

Front Oral Health· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.
Rom Leidner, Nelson Sanjuan Silva, Huayu Huang, David Sprott, Chunhong Zheng

N Engl J Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
David S Hong, Olivier Rixe, Vi K Chiu, Patrick M Forde, Tomislav Dragovich, Rom Leidner

Clin Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Corey C Foster, Marcus A Couey, Sara E Kochanny, Arun Khattri, Rajesh K Acharya, Rom S Leidner

Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Rom Leidner

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Robert L Ferris, William C Spanos, Rom Leidner, Anthony Gonçalves, Uwe M Martens

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection.
Shay Sharon, Jason R Baird, Shelly Bambina, Gwen Kramer, Tiffany C Blair, Rom S Leidner

Oncotarget· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explant Modeling of the Immune Environment of Head and Neck Cancer.
Shay Sharon, Thomas Duhen, Shelly Bambina, Jason Baird, Rom Leidner

Front Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Rom Leidner, Marka Crittenden, Kristina Young, Hong Xiao, Yaping Wu

J Immunother Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, Eric Tran, Venkatesh Rajamanickam, Rom S Leidner

Nat Commun· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis